Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets

Aoife M. Ryan, Michelle Duong, Laura Healy, Stephen A. Ryan, Niyati Parekh, John V. Reynolds, Derek G. Power

Research output: Contribution to journalArticle

Abstract

Background: Rates of distal and junctional adenocarcinomas are increasing in Western countries. Methods: Systematic review of epidemiological evidence linking obesity to esophageal adenocarcinoma (EA) was performed for studies published from 2005 to 2010. The current understanding of obesity's role in the etiology and potential dysplastic progression of Barrett's esophagus (BE) to EA is reviewed. Results: Accumulating epidemiological studies provide evidence of obesity's role as a driving force behind the increasing rates of EA. The simplest construct is that obesity promotes reflux, causing chronic inflammation and BE, predisposing to adenocarcinoma. However, as obesity is positively associated with the prevalence of many cancers, other mechanisms are important. A link may exist between fat distribution patterns and the risk of BE and EA. Altered metabolic profiles in the metabolic syndrome (MetS) may be a key factor in cell cycle/genetic abnormalities that mark the progression of BE towards cancer. Research highlighting a unique role of MetS in the length of BE, and its association with systemic inflammation and insulin resistance is discussed, as well as adipokine receptor expression in both BE and esophageal epithelium, and how MetS and the systemic response impacts on key regulators of inflammation and tumorigenesis. Conclusions/impact: Obesity is positively associated with EA. The systemic inflammatory state consequent on the altered metabolism of obese patients, and the associated impact of adipocytokines and pro-coagulant factors released by adipocytes in central fat, may underlie obesity's relationship to this cancer. Novel therapeutic agents that may antagonize adipo-cytokines and potentially offer a promising role in cancer therapy are discussed.

Original languageEnglish (US)
Pages (from-to)309-319
Number of pages11
JournalCancer Epidemiology
Volume35
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Barrett Esophagus
Epidemiology
Adenocarcinoma
Obesity
Adipokine Receptors
Inflammation
Fats
Neoplasms
Coagulants
Adipokines
Metabolome
Esophageal Neoplasms
Adipocytes
Insulin Resistance
Epidemiologic Studies
Cell Cycle
Carcinogenesis
Epithelium
Cytokines
Therapeutics

Keywords

  • Adenocarcinoma
  • Adipokines
  • Esophageal cancer
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology

Cite this

Obesity, metabolic syndrome and esophageal adenocarcinoma : Epidemiology, etiology and new targets. / Ryan, Aoife M.; Duong, Michelle; Healy, Laura; Ryan, Stephen A.; Parekh, Niyati; Reynolds, John V.; Power, Derek G.

In: Cancer Epidemiology, Vol. 35, No. 4, 08.2011, p. 309-319.

Research output: Contribution to journalArticle

Ryan, Aoife M. ; Duong, Michelle ; Healy, Laura ; Ryan, Stephen A. ; Parekh, Niyati ; Reynolds, John V. ; Power, Derek G. / Obesity, metabolic syndrome and esophageal adenocarcinoma : Epidemiology, etiology and new targets. In: Cancer Epidemiology. 2011 ; Vol. 35, No. 4. pp. 309-319.
@article{d9513389415b4ba98532e9a4dbb45807,
title = "Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets",
abstract = "Background: Rates of distal and junctional adenocarcinomas are increasing in Western countries. Methods: Systematic review of epidemiological evidence linking obesity to esophageal adenocarcinoma (EA) was performed for studies published from 2005 to 2010. The current understanding of obesity's role in the etiology and potential dysplastic progression of Barrett's esophagus (BE) to EA is reviewed. Results: Accumulating epidemiological studies provide evidence of obesity's role as a driving force behind the increasing rates of EA. The simplest construct is that obesity promotes reflux, causing chronic inflammation and BE, predisposing to adenocarcinoma. However, as obesity is positively associated with the prevalence of many cancers, other mechanisms are important. A link may exist between fat distribution patterns and the risk of BE and EA. Altered metabolic profiles in the metabolic syndrome (MetS) may be a key factor in cell cycle/genetic abnormalities that mark the progression of BE towards cancer. Research highlighting a unique role of MetS in the length of BE, and its association with systemic inflammation and insulin resistance is discussed, as well as adipokine receptor expression in both BE and esophageal epithelium, and how MetS and the systemic response impacts on key regulators of inflammation and tumorigenesis. Conclusions/impact: Obesity is positively associated with EA. The systemic inflammatory state consequent on the altered metabolism of obese patients, and the associated impact of adipocytokines and pro-coagulant factors released by adipocytes in central fat, may underlie obesity's relationship to this cancer. Novel therapeutic agents that may antagonize adipo-cytokines and potentially offer a promising role in cancer therapy are discussed.",
keywords = "Adenocarcinoma, Adipokines, Esophageal cancer, Metabolic syndrome, Obesity",
author = "Ryan, {Aoife M.} and Michelle Duong and Laura Healy and Ryan, {Stephen A.} and Niyati Parekh and Reynolds, {John V.} and Power, {Derek G.}",
year = "2011",
month = "8",
doi = "10.1016/j.canep.2011.03.001",
language = "English (US)",
volume = "35",
pages = "309--319",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Obesity, metabolic syndrome and esophageal adenocarcinoma

T2 - Epidemiology, etiology and new targets

AU - Ryan, Aoife M.

AU - Duong, Michelle

AU - Healy, Laura

AU - Ryan, Stephen A.

AU - Parekh, Niyati

AU - Reynolds, John V.

AU - Power, Derek G.

PY - 2011/8

Y1 - 2011/8

N2 - Background: Rates of distal and junctional adenocarcinomas are increasing in Western countries. Methods: Systematic review of epidemiological evidence linking obesity to esophageal adenocarcinoma (EA) was performed for studies published from 2005 to 2010. The current understanding of obesity's role in the etiology and potential dysplastic progression of Barrett's esophagus (BE) to EA is reviewed. Results: Accumulating epidemiological studies provide evidence of obesity's role as a driving force behind the increasing rates of EA. The simplest construct is that obesity promotes reflux, causing chronic inflammation and BE, predisposing to adenocarcinoma. However, as obesity is positively associated with the prevalence of many cancers, other mechanisms are important. A link may exist between fat distribution patterns and the risk of BE and EA. Altered metabolic profiles in the metabolic syndrome (MetS) may be a key factor in cell cycle/genetic abnormalities that mark the progression of BE towards cancer. Research highlighting a unique role of MetS in the length of BE, and its association with systemic inflammation and insulin resistance is discussed, as well as adipokine receptor expression in both BE and esophageal epithelium, and how MetS and the systemic response impacts on key regulators of inflammation and tumorigenesis. Conclusions/impact: Obesity is positively associated with EA. The systemic inflammatory state consequent on the altered metabolism of obese patients, and the associated impact of adipocytokines and pro-coagulant factors released by adipocytes in central fat, may underlie obesity's relationship to this cancer. Novel therapeutic agents that may antagonize adipo-cytokines and potentially offer a promising role in cancer therapy are discussed.

AB - Background: Rates of distal and junctional adenocarcinomas are increasing in Western countries. Methods: Systematic review of epidemiological evidence linking obesity to esophageal adenocarcinoma (EA) was performed for studies published from 2005 to 2010. The current understanding of obesity's role in the etiology and potential dysplastic progression of Barrett's esophagus (BE) to EA is reviewed. Results: Accumulating epidemiological studies provide evidence of obesity's role as a driving force behind the increasing rates of EA. The simplest construct is that obesity promotes reflux, causing chronic inflammation and BE, predisposing to adenocarcinoma. However, as obesity is positively associated with the prevalence of many cancers, other mechanisms are important. A link may exist between fat distribution patterns and the risk of BE and EA. Altered metabolic profiles in the metabolic syndrome (MetS) may be a key factor in cell cycle/genetic abnormalities that mark the progression of BE towards cancer. Research highlighting a unique role of MetS in the length of BE, and its association with systemic inflammation and insulin resistance is discussed, as well as adipokine receptor expression in both BE and esophageal epithelium, and how MetS and the systemic response impacts on key regulators of inflammation and tumorigenesis. Conclusions/impact: Obesity is positively associated with EA. The systemic inflammatory state consequent on the altered metabolism of obese patients, and the associated impact of adipocytokines and pro-coagulant factors released by adipocytes in central fat, may underlie obesity's relationship to this cancer. Novel therapeutic agents that may antagonize adipo-cytokines and potentially offer a promising role in cancer therapy are discussed.

KW - Adenocarcinoma

KW - Adipokines

KW - Esophageal cancer

KW - Metabolic syndrome

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=79960616415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960616415&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2011.03.001

DO - 10.1016/j.canep.2011.03.001

M3 - Article

C2 - 21470937

AN - SCOPUS:79960616415

VL - 35

SP - 309

EP - 319

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 4

ER -